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In Utero Exposure to Bioactive Food Components
and Mammary Cancer Risk (R21)
In utero is a vulnerable period. In utero exposures are
important determinants of some cancers occurring in
children and young adults. For example, exposure to
ionizing radiation in utero promotes childhood
leukemia, and maternal use of diethylstilbestrol during
pregnancy has been linked to clear-cell adenocarci-
noma of the vagina in their daughters. In addition,
maternal diets, speciﬁcally the consumption of vegeta-
bles, fruits, and protein, are linked to decreased risk of
childhood leukemia.
The prenatal period is critical in the development
of the mammary gland. During this time, the mam-
mary gland is in a largely undifferentiated state, making
it particularly vulnerable to a host of environmental
forces. Inappropriate nutritional status or exposure to
environmental chemicals and the accompanied alter-
ation in growth and endocrine homeo-stasis may per-
manently change the fetus structure, physiology, and
metabolism, thereby predisposing it to various diseases
in later life, including mammary cancer.
In utero exposures and human breast cancer risk.
Epidemiological studies suggest that altering the
intrauterine nutritional status can increase mammary
cancer risk. Failure of the materno–placental supply
line to satisfy fetal nutrient requirements can result in
a range of fetal adaptations and developmental
changes. Birth weight is a gross surrogate marker for
shifts in a host of metabolic processes. Many, but not
all, studies reveal a positive relationship between
increased birth weight and breast cancer risk.
Likewise, other indicators of fetal size such as
increased placental weight and birth length are posi-
tively correlated with breast cancer risk in the off-
spring. Recent studies suggest that birth weight is
independent from neonatal growth patterns and the
timing of puberty as a risk factor for breast cancer.
In addition to nutrition, the hormonal environ-
ment in the womb may play an important role in pro-
gramming lifelong risk for breast cancer in female
offspring. A reduction in circulating levels of estrogens
and insulin-like growth factor-1 (IGF-1), and/or ele-
vated levels of progesterone, androgens, human chori-
onic gonadotrophin, IGF-1 binding proteins 1 and 3,
cortisol, and insulin have been associated with
reduced risk. Such hormonal and growth factor
changes are observed during preeclampsia. Maternal
preeclampsia has been associated with a reduction in
the female offspring's later risk for breast cancer after
adjustment for a variety of potential confounders.
Mammary gland development, dietary modifica-
tion, and breast cancer risk. Proliferation of primitive
ductal structures in the newborn breast leads to
branching and terminal end buds (TEBs). The expan-
sion of TEBs represents an opportunity for malignant
transformation because they contain pluripotent
mammary stem cells. In fact, in utero exposures that
bring about an increase in TEBs coincide with
increased mammary carcinogenesis. Evidence exists
that providing maternal diets that contain elevated
amounts of n-6 polyunsaturated fatty acids (PUFAs)
and genistein not only increased TEBs, but also
reduced the differentiation of TEBs to lobuloalveolar
units. These diets also increased subsequent chemi-
cally induced mammary cancer in the offspring. In
addition, prenatal exposure to environmental agents,
such as bisphenol A or dioxin, results in alteration in
the development of the mammary gland that may
predispose to the development of cancers later in life.
Some of this response may relate to changes in hor-
monal and growth factor status, including estrogen
and IGF-1.
Estrogen, dietary modification, and breast cancer
risk. Greater estrogen exposure throughout a woman’s
life has been identiﬁed as a major risk factor for the
development of breast cancer. In utero exposures to the
mammary gland can achieve concentrations 10–100
times the estrogen levels occurring later in life. Dietary
factors, such as genistein and fat, which influence
estrogen exposure to the fetus, are related to subse-
quent cancer risk in several model systems. However,
the response may not be totally explained by estradiol,
since n-3 fatty acid– rich diets fed to pregnant rats ele-
vate this hormone, but reduce mammary cancer inci-
dence in the offspring.
It is possible that intrauterine exposure to other
hormones, environmental hormone mimics, or antag-
onists may also affect breast cancer susceptibility.
Androgen exposure in utero may confer long-term pro-
tection against breast cancer by antagonizing the
effects of estrogens on fetal breast ductal development.
Dietary fatty acids, phytoestrogens, alcohol, and
lycopene are among the various bioactive food com-
ponents reported to influence androgen concentra-
tions. Environmental agents with estrogenic agonist or
antagonist activity may also alter gene expression dur-
ing development that may lead to functional deﬁcits
later in life that predispose to cancer development.
Thus, there is the need for future studies focusing on
uncovering the mechanisms responsible for the pro-
tective and detrimental effects of exposure to bioactive
food components and other environmental agents in
utero on breast cancer risk. These studies should
attempt to address more comprehensively the changes
in all potentially relevant pregnancy hormones and
growth factors.
IGF, dietary modiﬁcation, and breast cancer risk.
The IGF-1 system may play a crucial role in the
increased risk that heavier newborns have of develop-
ing breast cancer later in life. Birth weight is positively
associated with increased insulin and IGF-1 concentra-
tions. Analysis of mammary gland development in
knockout mice made deﬁcient in IGF-I or in the IGF-
I receptor demonstrates the importance of the IGF sys-
tem for normal mammary gland development because
these mice have diminished TEB development.
Observational and preclinical studies provided added
evidence that one or more components of the IGF-1
system may be intimately linked to the process of car-
cinogenesis in the mammary gland. Transgenic mice
that overexpress IGF-I or II display speciﬁc alterations
in mammary gland development such as an inhibition
of mammary cell apoptosis following weaning and an
increased incidence of mammary tumors. Thus,
increased exposure to IGF-1 in utero may serve as a
marker for the relationship between fetal growth and
adult cancer susceptibility.
Although the effects of in utero exposure to
dietary components have been inadequately exam-
ined, considerable evidence exists for their ability to
modify IGF-1 concentrations and mammary cancer
susceptibility postnatally. Postnatal caloric restriction
decreases IGF-1 and decreases mammary tumor
growth and metastases. Furthermore, postnatal soy
phytochemicals combined with green tea synergisti-
cally inhibited mammary tumor growth and
depressed serum IGF-1 levels in mice. Future studies
are warranted to determine whether in utero exposure
to dietary manipulations that modulate IGF-1 expres-
sion will inﬂuence subsequent breast cancer risk.
Epigenetics, dietary modiﬁcation, and breast cancer
risk. Maternal nutritional status can also alter the epi-
genetic state of the fetal genome and imprint gene
expression levels with lifelong consequences. Loss of
imprinting is the silencing of active imprinted genes
or the activation of silent imprinted genes, and is one
of the most common epigenetic changes associated
with the development of a wide variety of tumors.
For example, loss of imprinting of IGF-2 has been
associated with many different types of cancer,
including mammary tumor development. H19, a
tumor suppressor gene located directly downstream
from IGF-2, is also genomically imprinted and is
associated with various cancers. Furthermore, the
hereditary disorder Beckwith-Wiedemann syndrome,
which predisposes to cancer and causes prenatal over-
growth, involves alterations in IGF-2 and H19
imprinting. Several lines of evidence support the rela-
tionship between maternal nutrition and epigenetic
changes in their offspring. First, a deficiency of
amino acids results in marked reduction in genomic
DNA methylation and aberrant expression of the
normally silent paternal H19 allele in cultured mouse
embryos. Second, uteroplacental insufﬁciency causes
hypomethylation and increased histone acetylation in
postnatal rat liver. Third, maternal supplementation
of methyl donors and cofactors (folic acid, vitamin B-
12, choline, and betaine) increases CpG methylation
at the Avy locus of agouti mouse pups which causes a
shift from a yellow to an agouti coat. The methyla-
tion patterns are retained into adulthood and are
linked with a lower risk of cancer, diabetes, obesity,
and prolonged life. Thus, epigenetic changes may
provide a molecular mechanism for the impact of
maternal nutrition or environmental chemical expo-
sures on postnatal disease susceptibility and deserves
future research.
Investigators may choose from the full range of
preclinical approaches. The use of genetically engi-
neered animal models, including transgenic or knock-
outs, such as those available through the mouse
models of human cancer consortium (MMHCC;
http://emice.nci.nih.gov/) are encouraged. Studies are
encouraged that apply new high-throughput genomic,
epigenomic, proteomic, and metabolomic technolo-
gies to determine how dietary and/or environmental
chemical exposures in utero inﬂuence adult breast can-
cer susceptibility.
Illustrative examples for the development of
R21 applications include, but are not limited to, the
following examples: 1) utilization of transgenic and
knockout mouse models of human mammary cancer
to identify molecular sites of action of bioactive food
components in cancer prevention; 2) examination of
the role of moderate caloric restriction in utero on
hormone concentrations (i.e., estrogen, insulin, ICF-
1), and mammary cancer prevention; 3) evaluation
of synergistic effects of exposure to bioactive food
components in utero and subsequent mammary can-
cer risk; 4) evaluation of IGF-2, H19, and other
imprinted genes after exposure to bioactive food
components in utero and subsequent mammary can-
cer risk; 5) examination of the role of in utero expo-
sures to environmental agents, such as mycotoxins,
heterocylic amines, bisphenol A, pththlates, and
other agents with endocrine-like agonist or antago-
nist activity and subsequent mammary cancer risk;
and 6) examination of the interaction of in utero
exposures to bioactive food components (e.g., phy-
toestrogens) and exposures to environmental agents
in the etiology of breast cancer later in life.
This FOA will use the NIH Exploratory/
Developmental Research Grant (R21) award mecha-
nism. As an applicant, you will be solely responsible
for planning, directing, and executing the proposed
project.
This FOA uses just-in-time concepts. It also uses
the modular budget formats: See the ModularFellowships, Grants, & Awards
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Applications and Awards section of the NIH Grants
Policy Statement. Speciﬁcally, if you are submitting
an application with direct costs in each year of
$250,000 or less (excluding consortium Facilities and
Administrative [F&A] costs), use the PHS398
Modular Budget component provided in the SF424
(R&R) Application Package and SF424 (R&R)
Application Guide (see specifically Section 5.4,
Modular Budget Component, of the Application
Guide).
Exploratory/developmental grant support is for
new projects only; competing renewal (formerly com-
peting continuation) applications will not be
accepted. Up to two resubmissions (formerly revi-
sions/amendments) of a previously reviewed
exploratory/developmental grant application may be
submitted. See NOT-OD-03-041, which was pub-
lished in the NIH Guide on 7 May 2003.
Applicants must download the SF424 (R&R)
application forms and SF424 (R&R) Application
Guide for this FOA through Grants.gov/Apply.
Note: Only the forms package directly attached to
a speciﬁc FOA can be used. You will not be able to use
any other SF424 (R&R) forms (e.g., sample forms,
forms from another FOA), although some of the
Attachment ﬁles may be useable for more than one
FOA.
For further assistance, contact GrantsInfo; 301-
435-0714 (telecommunications for the hearing
impaired: TTY 301-451-0088) or by e-mail:
GrantsInfo@nih.gov.
Prepare all applications using the SF424 (R&R)
application forms and in accordance with the SF424
(R&R) Application Guide (MS Word or PDF).
The SF424 (R&R) Application Guide is critical
to submitting a complete and accurate application to
NIH. There are ﬁelds within the SF424 (R&R) appli-
cation components that, although not marked as
mandatory, are required by NIH (e.g., the Credential
log-in field of the Research & Related Senior/Key
Person Proﬁle component must contain the PD/PI’s
assigned eRA Commons User ID). Agency-specific
instructions for such ﬁelds are clearly identiﬁed in the
Application Guide. For additional information, see
Tips and Tools for Navigating Electronic Submission
on the front page of Electronic Submission of Grant
Applications.
The application submission dates are avail-
able at http://grants.nih.gov/grants/funding/
submissionschedule.htm. The complete version of
this PA is available at http://grants.nih.gov/grants/
guide/pa-ﬁles/PA-06-277.html.
Contacts: Cindy D. Davis, National Cancer
Institute (NCI), Division of Cancer Prevention,
National Cancer Institute, 6130 Executive
Boulevard, EPN Room 3159, MSC 7328 Bethesda,
MD 20892-7328 USA (for U.S. Postal Service
express or regular mail), Rockville, MD 20852 USA
(for express/courier delivery), 301-594-9692,
fax: 301-480-3925, e-mail: davisci@mail.nih.gov;
Mary Frances Picciano, NIH Office of Dietary
Supplements (ODS), Ofﬁce of Dietary Supplements,
Ofﬁce of the Director, National Institutes of Health,
6100 Executive Boulevard, Room 3B01, MSC 7517
Bethesda, MD 20892-7517 USA (for U.S. Postal
Service express or regular mail) Rockville, MD 20852
USA (for express/courier delivery) 301-435-3608,
e-mail: piccianM@mail.nih.gov; Jerry Heindel,
National Institute of Environmental Health Sciences
(NIEHS), Cellular, Organs and Systems
Pathobiology Branch, Division of Extramural
Research and Training, PO Box 12233 RTP, NC,
27709 USA, 79 T.W. Alexander Drive, 4401
Building (for express/courier service) 919-541-0781,
fax: 919-541-5064, e-mail: heindelj@niehs.nih.gov.
Reference PA-06-277
NIH Pathway to Independence (PI) Award
(K99/R00)
One of the most challenging transitions in any
research career is the transition from postdoctoral
trainee to independent scientist. Recent reports from
the National Research Council of the National
Academies of Science (Bridges to Independence:
Fostering the Independence of New Investigators in
Biomedical Research http://books.nap.edu/cata-
log/11249.html, and Advancing the Nation’s Health
Needs: NIH Research Training Program http://www.
nap.edu/booksearch.php?term=%22nrc+analy-
sis%22&isbn=0309094275) have highlighted the
need for enhanced efforts to foster the transition of
postdoctoral scientists from mentored environments
to independence.
The NIH data indicate that the average age of
ﬁrst-time (new) principal investigators obtaining R01
research funding from the NIH has risen to 42 years
for Ph.D. degree holders and 44 years for M.D. and
M.D./Ph.D. degree holders. This trend must be
curtailed in order to capture the creativity and innova-
tion of new independent investigators in their early
career stages to address our nation’s biomedical,
behavioral, and clinical research needs. 
The primary goal of this pilot initiative is to facili-
tate receiving an R01 award earlier in a research career
and to assist investigators in securing a stable research
position during the critical transition stage of their
career.
In addition to this initiative, NIH Institutes and
Centers support a variety of mentored career develop-
ment programs designed to foster the transition of new
investigators to research independence. These pro-
grams span research career development opportunities
for investigators who have made a commitment to
focus on patient-oriented research through the
Mentored Patient-Oriented Research Career
Development Award (K23) http://grants.nih.gov/
grants/guide/pa-files/PA-05-143.html to research
career development opportunities for individuals with
highly developed quantitative skills seeking to inte-
grate their expertise in research relevant to the mission
of NIH (K25) http://grants.nih.gov/grants/guide/
pa-ﬁles/PA-06-087.html. Information describing all
NIH Career Development Award programs can be
found at http://grants.nih.gov/training/careerdevelop-
mentawards.htm.
The NIH Pathway to Independence Award will
provide up to 5 years of support consisting of two
phases. The initial mentored phase will provide sup-
port for salary and research expenses for up to 2 years
for the most promising and exceptionally talented new
investigators who have no more than 5 years of post-
doctoral research training experience at the time of ini-
tial application or subsequent resubmission(s). This
initial phase of mentored support will allow the candi-
date time to complete research, publish results, and
bridge to an independent research position. As part of
the application, the candidate must propose a research
project that will also be pursued as an independent
investigator during the second phase of the award. The
candidate and mentors together will be responsible for
all aspects of the mentored career development and
research program. An individual may submit an appli-
cation from an extramural or intramural sponsoring
institution/organization that has a rich and extensive
research program in the area of interest as well as the
faculty, facilities, and resources to support the pro-
posed research endeavor. The individual must select an
appropriate mentor with a track record of funded
research related to the selected research topic and expe-
rience as a supervisor and mentor. The sponsoring
institution must ensure that the candidate has the pro-
tected time needed to conduct the proposed research.
Following the mentored phase, the individual
may request up to three years of support to transition,
as an independent scientist, to an extramural sponsor-
ing institution/organization to which the individual
has been recruited. This support is to allow the indi-
vidual to continue to work toward establishing his/her
own independent research program and prepare an
application for regular research grant support (R01).
Support for the independent phase, however, is not
automatic and is contingent upon being accepted by
an extramural institution and the successful NIH pro-
grammatic review of the individual’s mentored phase
of the award.
This funding opportunity will use the new com-
bination K99/R00 funding mechanism. As an appli-
cant, the candidate and his/her mentor are jointly
responsible for planning, directing, and executing the
proposed mentored phase of the research project.
This funding opportunity uses the just-in-time
budget concepts. It also uses the nonmodular budget
format described in the PHS 398 application instruc-
tions (see http://grants.nih.gov/grants/funding/
phs398/phs398.html). The applicant should follow
the instructions for budget information described in
the PHS 398, Section III, providing only the total
direct costs requested for each year and the entire pro-
posed period of support and budget justification
information. 
The PHS 398 application instructions are avail-
able at http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. Applicants
must use the currently approved version of the PHS
398. For further assistance contact Grants Info, 301-
435-0714 (telecommunications for the hearing
impaired: TTY 301-451-0088) or by e-mail:
GrantsInfo@nih.gov.
Applications must be prepared using the most
current PHS 398 research grant application instruc-
tions and forms. Applications must have a Dun &
Bradstreet (D&B) Data Universal Numbering System
(DUNS) number as the universal identifier when
applying for federal grants or cooperative agreements.
The D&B number can be obtained by calling 866-
705-5711 or through the web site at http://www.
dnb.com/us/. The D&B number should be entered
on line 11 of the face page of the PHS 398 form.
The application submission dates for this PA are
available at http://grants.nih.gov/grants/funding/sub-
missionschedule.htm. The complete version of this
PA is available at http://grants.nih.gov/grants/guide/
pa-ﬁles/PA-06-133.
Contacts: Please see http://grants.nih.gov/
grants/guide/contacts/pa-06-133_contacts.htm for
this PA. Reference: PA-06-133
Research On Ethical Issues In Human Subjects
Research (R03) 
The common characteristic of the small grant is provi-
sion of limited funding for a short period of time.
Examples of the types of projects that ICs support with
the R03 include pilot or feasibility studies; secondary
analysis of existing data; and small, self-contained
research projects
This Funding Opportunity Announcement
(FOA) issued by the National Institutes of Health(NIH) solicits Small Grant (R03) applications address-
ing ethical issues that accompany the conduct of
research involving human subjects.
The purpose of this funding opportunity
announcement is to solicit research addressing the ethi-
cal challenges of human subjects research in order to
optimize the protection of human subjects and
enhance the ethical conduct of human subjects
research.
Recent developments in biomedical and behav-
ioral research, which include the rapid growth of new
interventions and technologies, increasing involvement
of foreign populations in human subjects research, and
concerns about ﬁnancial conﬂicts of interest among
researchers, challenge investigators’ abilities to interpret
and apply the regulations. Other situations (e.g.,
research with vulnerable populations, research on stig-
matizing diseases or conditions) may present difﬁcul-
ties for identifying strategies, procedures, and/or
techniques that will enhance/ensure the ethical involve-
ment of human subjects in research. Thus, research on
ethical issues in human subjects research is necessary to
enhance interpretation and application of ethical prin-
ciples and regulatory requirements.
The research design for studies on ethical issues in
human subjects research should be appropriate to the
nature of the project(s) proposed and the disciplines
involved. Given the conceptual and methodological
complexity of many of these research questions, inter-
disciplinary and collaborative projects are encouraged,
particularly those involving clinical researchers, ethi-
cists, and behavioral/social scientists.
In conducting research on ethical issues in human
subjects research, different conceptual frameworks for
ethics (e.g., principlism, deontology, utilitarianism,
rights, ethics of care) exist and may provide presuppo-
sitions and theoretical foundations from which bioethi-
cal questions can be formulated and tested. The
questions and strategies for testing these issues must be
consistent with existing federal requirements.
Currently, research supported by the Department of
Health and Human Services (DHHS; which includes
NIH) follows the Code of Federal Regulations—
Protection of Human Subjects (45 CFR Part 46). For
research conducted internationally, alternative guide-
lines that describe protections equivalent to those
required by 45 CFR 46 may be used (http://www.hhs.
gov/ohrp/humansubjects/assurance/ﬁlasur.htm), such
as those developed by the World Health Organization,
the Council for International Organizations of Medical
Sciences, and other internationally recognized groups.
This FOA seeks Small Grant (R03) applications
for empirical or conceptual research that address the
ethical challenges of research involving human subjects
with the goal of optimizing protections. See http://
grants.nih.gov/grants/funding/r03.htm for a descrip-
tion of the NIH Small Grant Program. The NIH is
also issuing FOAs on the same topics using two other
grant mechanisms: The R01 will support empirical
research; the R21 will support conceptual as well as
empirical research.
See http://grants.nih.gov/grants/guide/contacts/
pa-06-367_368_369_differences.doc for an explana-
tion of R01, R21, and R03 mechanisms.
Examples of the types of topics that would be
appropriate for applications submitted under these
announcements include, but are not limited to, the fol-
lowing: 
1) Assessing risks in human subjects research:
a) Assess how perceptions of risk may differ among
investigators, IRB members, and potential subjects
and their families, groups, and communities. Examine
how features of the research, context of the research,
or characteristics of research subjects (e.g., age, health
status and stage of disease including those near the
end of life, ethnic/cultural background, cognitive
capacity, emotional or mental state, social status, sex,
incarceration, enthusiasm/optimistic expectation
about research) may alter risk perception. Identify and
evaluate strategies to respond to differing perceptions
of risks by stakeholders. b) Assess the severity and fre-
quency of social, psychological, and/or economic
harms (e.g., stigma, discrimination, personal and
familial distress, depression, breaches of conﬁdential-
ity, loss of insurance coverage, loss of employment,
loss of housing, loss of benefits, domestic violence,
incarceration) that may be associated with participa-
tion in or withdrawal from research. Develop and test
methods to evaluate prospectively and minimize psy-
chosocial risks in research. For example, formative
research in a community may identify social or cul-
tural issues or concerns before the conduct of research.
Researchers may compare different methods to reduce
risk, such as, for example, modifications to study
design to reduce risks, or provision of additional ser-
vices to research subjects. c) Develop and test models
of prospective risk assessment in human subjects
research, including, but not limited to, risks of new
technologies. Risk assessment can be particularly chal-
lenging in the case of early human trials of new tech-
nologies. How can preclinical data best be used to
assess the risk of new technologies used in ﬁrst human
trials? How can estimates of risk be translated from
animal and in vitro studies to clinical trials in human
populations? How can the need to advance new tech-
nologies into clinical application be balanced with
caution about exposing research subjects to unknown
risks, and speciﬁcally what scientiﬁc and ethical crite-
ria are relevant to making these determinations? How
can an assessment of the risks and beneﬁts of research
take into account the severity of disease and the
urgency of need for new treatments as well as the pos-
sibility of therapeutic misconception? d) Develop
models for design of clinical trials of new technologies.
What study designs are most appropriate to allow
consideration of safety issues in the ﬁrst human trials?
How can information from clinical trials of related
interventions be used in designing new trials and in
assessing safety data? e) Assess risks to privacy and con-
ﬁdentiality. Speciﬁc topics might include (but are not
limited to): models for assessing conﬁdentiality risks in
research, including interventional research, social and
behavioral research, and research with data and speci-
mens; research to assess the use and understanding of
certiﬁcates of conﬁdentiality and the role they play in
IRB assessments of risks to subjects.
2. Issues in informed consent: a) Identify and
evaluate strategies, procedures, or techniques for
improving comprehension and voluntariness in the
process of informed consent for research. This could
include evaluation of communication processes that
take place before, during, or after the research, and/or
measurement of comprehension, willingness to partic-
ipate or continue participation, assent, and attitudes
toward research. Examine how different aspects of the
informed consent process affect these outcomes,
including such parameters as: mode of presentation
(e.g. oral, written, graphic, video); readability, com-
plexity, and format of the language used; presentation
of positive or negative aspects of participation in
research, relative emphasis on beneﬁts or burdens of
participation; characteristics of the subject, such as
language preference, age, sex, health status, education,
emotional or mental state, cognitive capacity, cultural
or ethnic background, views about medical profes-
sionals, and personal motivations; contextual features
or circumstances in which informed consent takes
place, including characteristics of the research staff;
presence of an interpreter, location of the research
(e.g., research hospital, private ofﬁce, home); involve-
ment of family members; involvement of subject
advocates. b) Evaluate different methods and identify
best-practice strategies for consulting with communi-
ties in the United States and/or other countries
regarding comprehension, willingness to participate,
or willingness to continue with research at the individ-
ual, group, community, or population level. c) Assess
stakeholder attitudes regarding re-contacting subjects
to obtain informed consent for additional uses of their
data or to invite participation in other studies; exam-
ine the effect of re-contact on comprehension and
willingness to participate. d) Assess the extent to
which prospective subjects’ decisions about joining
research are voluntary. Explore models of decision
making and the effect of situational and individual
characteristics on the decision-making process.
Evaluate investigators’ attitudes regarding participants’
decision-making process. Assess the effects of incen-
tives such as monetary compensation, provision of
medical care, or other beneﬁts of research on decision
making and perceptions of research by potential or
actual participants or study communities. e) Assess the
impact of communicating or not communicating
individual test results, incidental findings, study
progress, and/or study results on participants’ willing-
ness to continue participating in research and/or on
attitudes towards research. f) Assess the ethical and
legal implications of various models to handle illegal
behavior by participants enrolled in or being screened
for a study. g) Knowledge or perception of conﬂict of
interest on the part of the investigator(s) or institu-
tion: Assess the impact of disclosing varying degrees of
ﬁnancial conﬂicts of interest involving the principal
investigator, members of oversight committees, spon-
sor, institution, etc., on subjects’ willingness to partici-
pate and/or continue with research, and/or subjects’
understanding of the research.
3. International research: a) Evaluate different
methods and identify best-practice strategies for con-
sulting with communities and stakeholders in host
countries as well as in the United States during all
phases of human subjects research (planning, execu-
tion, and dissemination of results). Identify and test
models from participatory research that are appropriate
in different settings. Community consultation might
address issues such as the signiﬁcance or priority of the
research project in light of local public health priorities;
choice of timing of consultation during the develop-
ment of the research plan; assessment of community
members’ likely comprehension of the research; com-
munity perspectives on the design of the research; the
willingness of community members to join or continue
participation in research; and plans for feedback of
information to communities during and after the
research. b) Identify and evaluate strategies for investi-
gators and sponsors of research to build trust and
collaborative partnerships with host country communi-
ties, investigators and health care delivery systems.
c) Evaluate how foreign human subjects protection sys-
tems are applied to U.S.-funded international research.
Evaluate the extent to which such protections could
satisfy U.S. regulatory requirements for equivalent pro-
tections. Evaluate experiences of investigators dealing
with foreign regulatory systems and develop models for
dealing with multiple human subjects protections sys-
tems and standards. d) Identify and evaluate strategies
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political and cultural environments and different atti-
tudes toward personal autonomy. e) Develop methods
to assess vulnerability, including economic and social
vulnerability, in resource-limited settings and evaluate
remedies to enhance human subjects protections of
vulnerable populations or groups. f) Address the ethical
and practical aspects of providing medical care in the
context of human subjects research in low-resource set-
tings, particularly in the international setting. Assess
stakeholders’ perceptions of requirements or requests
to provide ancillary care during the conduct of human
subjects research. g) Identify and evaluate strategies to
build health care and/or human subjects research
capacity; assess durability of capacity building strate-
gies; recommend best practices.
4. Study design in clinical trials and its relation-
ship to medical care: a) Identify the ethics implica-
tions of speciﬁc scientiﬁc parameters in clinical trial
design, such as the choice of appropriate control
arm(s) in clinical trials of biomedical and/or behav-
ioral interventions. Develop and/or evaluate strategies
to address study design issues that pose particular eth-
ical and scientiﬁc challenges. b) Evaluate how differ-
ent study designs might entail different risks or
beneﬁts to subjects or to society at large in terms of
social value of the research, including issues such as
social acceptability, protection of the welfare of sub-
jects in the trial, scientiﬁc rigor, relevance, feasibility,
and timeliness. c) Evaluate the scientiﬁc and ethical
implications of different types of controlled trials,
including consideration of choice of flexible versus
controlled conditions, physician or patient prefer-
ences in medical care, and strategies for handling sci-
entiﬁc and medical disputes about usual or standard
care. These issues can arise in studies that include bio-
medical interventions, behavioral interventions, or
both. d) Evaluate the scientiﬁc and ethical acceptabil-
ity of placebo-controlled trials in different scenarios,
the societal and individual beneﬁt from different trial
designs and criteria to guide the conduct of trials
using placebo or active controls.
5. Research oversight: IRBs, DSMBs, and COI
committees: a) Identify and evaluate strategies to
improve the oversight of protections for human sub-
jects by IRBs. Examples might include: i) assessment
of different models of IRB review, such as cooperative
review arrangements for multisite or complex research
protocols; collaborative IRB arrangements for multi-
site studies or complex research projects; collaborative
IRB arrangements in international studies; or division
of labor among multiple IRBs reviewing the same
research plan; ii) development and testing of models
for effective communication, delegation of responsi-
bilities, and joint decision making of multiple institu-
tional review boards in international research; iii)
assessment of stakeholder attitudes toward different
IRB models including views of researchers, IRB mem-
bers, institutional ofﬁcials, community members, and
research sponsors; iv) development of appropriate out-
comes measures and quality indicators for the IRB
review process for measurement of adequate protec-
tion of human subjects; development and testing of a
framework for assessing IRB review quality; determi-
nation of when variability in IRB outcomes would be
acceptable and when such variation would indicate
inconsistent quality. b) Develop and test models or
outcome measures for assessing the functioning of
data and safety monitoring boards (DSMB). For
example, develop and test models for effective com-
munication, delegation of responsibilities, and joint
decision making among multiple IRBs and DSMBs;
compare and evaluate different methods and strategies
for facilitating the submission and enhancing the
interpretation of adverse event reports submitted to
review bodies. Compare and evaluate different meth-
ods and strategies for identifying, reporting, and han-
dling adverse events, severe adverse events, or
unanticipated problems based on the perspectives of
individual participants, institutions, DSMBs, and/or
IRBs. c) Evaluate effectiveness of conﬂict of interest
(COI) committees. For example, identify and evaluate
strategies to address nonﬁnancial COI among research
teams, sponsors, advisory boards, or other stakehold-
ers. Assess the impact of perceived or real conﬂicts of
interest among members of oversight committees on
decision making about the acceptability of research
protocols, interpretations of adverse events, and/or
perceptions of “independence of review” by the
research community.
6. Research with specimens and data: a) Assess the
perspectives and attitudes of subjects about the use of
specimens and/or data in research, including special
cultural or religious beliefs and attitudes concerning
the use of discarded clinical specimens. b) Assess how
much subjects expect to know about how their speci-
mens and/or data will be used in research. c) Develop
novel approaches for obtaining informed consent for
research use of specimens and data collected during the
course of routine clinical care. d) Explore and develop
ways of addressing ethical issues related to the return of
individual research results to subjects, including studies
of associated risks and harms. e) Explore and develop
ways of addressing ethical issues related to intellectual
property and ownership of specimens. f) Explore issues
related to benefit sharing in the context of tissue
research. Identify models and mechanisms that can be
used to engage communities, sponsors, and researchers
in beneﬁt-sharing arrangements and assess the social
and ethical acceptability and practicability of these
arrangements. g) Identify and evaluate strategies for
balancing the responsibility for protecting and/or mini-
mizing disclosure of private information with the
obligation to maximize the social value of research
when identiﬁable data are collected via the Internet or
other electronic method; or preserved for secondary
analysis, e.g., a tissue or gene bank, data archive, or
warehouse.
7. Dissemination of research ﬁndings: a) Explore
when and how research results and incidental ﬁndings
should be reported and disseminated to lay communi-
ties, including research subjects and the general public.
b) Develop and evaluate methods for communicating
research results and incidental ﬁndings with medical
implications to research subjects and families.
c) Develop and evaluate scientiﬁc and ethical parame-
ters that should be considered when reporting general-
ized, aggregate research ﬁndings; develop and evaluate
methods for communicating the evolving and some-
times conﬂicting nature of scientiﬁc evidence to lay
audiences.
To assist you in identifying which NIH
Institute/Center most closely matches your research
topic, the following website provides additional
information about Institute/Center-speciﬁc research
interests that will be supported by this FOA: http://
grants.nih.gov/grants/guide/contacts/pa-06-
367_368_369_contacts.doc
This Funding Opportunity Announcement
(FOA) invites applications for small research projects
that can be carried out in a short period of time with
limited resources. The applicant will be solely responsi-
ble for planning, directing, and executing the proposed
project.
This FOA uses just-in-time concepts. It also uses
the modular budget formats (see the Modular
Applications and Awards section of the NIH Grants
Policy Statement). All applications submitted in
response to this FOA must use the modular budget
format. Speciﬁcally, if you are submitting an applica-
tion with direct costs in each year of $250,000 or less
(excluding consortium Facilities and Administrative
[F&A] costs), use the PHS398 Modular Budget com-
ponent provided in the SF424 (R&R) Application
Package and SF424 (R&R) Application Guide (see
speciﬁcally Section 5.4, Modular Budget Component,
of the Application Guide).
Competing renewal (formerly competing contin-
uation) applications will not be accepted for the R03
grant mechanism. Small grant support may not be
used for thesis or dissertation research. Up to two
resubmissions (formerly “revisions/amendments”) of a
previously reviewed small grant application may be
submitted as deﬁned in NIH Policy. See NOT-OD-
05-046 http://grants.nih.gov/grants/guide/notice-
ﬁles/NOT-OD-05-046.html 
For speciﬁc information about the R03 program,
see: http://grants.nih.gov/grants/funding/r03.htm.
Applicants must download the SF424 (R&R)
application forms and SF424 (R&R) Application
Guide for this FOA through Grants.gov/Apply.
Note: Only the forms package directly attached to
a speciﬁc FOA can be used. You will not be able to use
any other SF424 (R&R) forms (e.g., sample forms,
forms from another FOA), although some of the
“Attachment” ﬁles may be useable for more than one
FOA.
For further assistance contact GrantsInfo, 301-
435-0714 (telecommunications for the hearing
impaired: TTY 301-451-0088) or by e-mail:
GrantsInfo@nih.gov.
Prepare all applications using the SF424 (R&R)
application forms and in accordance with the SF424
(R&R) Application Guide (MS Word or PDF).
The SF424 (R&R) Application Guide is critical
to submitting a complete and accurate application to
NIH. There are ﬁelds within the SF424 (R&R) appli-
cation components that, although not marked as
mandatory, are required by NIH (e.g., the Credential
log-in field of the Research & Related Senior/Key
Person Proﬁle component must contain the PD/PI’s
assigned eRA Commons User ID). Agency-specific
instructions for such ﬁelds are clearly identiﬁed in the
Application Guide. For additional information, see
Tips and Tools for Navigating Electronic Submission”
on the front page of Electronic Submission of Grant
Applications.
The SF424 (R&R) application is comprised of
data arranged in separate components. Some compo-
nents are required, others are optional. The forms
package associated with this FOA in Grants.gov/
APPLY will include all applicable components,
required and optional.
The application submission dates for this PA are
available at http://grants.nih.gov/grants/funding/sub-
missionschedule.htm. The complete version of this PA
is available at http://grants/nih.gov/grants/guide/pa-
files/PAR-06-367. Paper applications will not be
accepted.
Contacts: The complete list of agency contacts is
available at http://grants/nih.gov/grants/guide/pa-ﬁles/
PAR-06-367. Reference: PAR-06-367.
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